Ep. 121 - ASCO, CRISPR IP & CStone
BioCentury This Week
00:00
Marade's Adograsib in Non Small Salon Cancer
The latest up date for marade's adograsib in non small salon cancer. mir s programm has had slightly higher response rates than lumicras from amjen nno consistently. But we've gradually been seeing the gap between these, these two programmes narrow. And i think the take away from the latest data for adograsi, which is under review by fda right now, suggest that there's not that much of a difference between these two caras g 12 c inhibiters.
Transcript
Play full episode
